AU2013255880B2 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
AU2013255880B2
AU2013255880B2 AU2013255880A AU2013255880A AU2013255880B2 AU 2013255880 B2 AU2013255880 B2 AU 2013255880B2 AU 2013255880 A AU2013255880 A AU 2013255880A AU 2013255880 A AU2013255880 A AU 2013255880A AU 2013255880 B2 AU2013255880 B2 AU 2013255880B2
Authority
AU
Australia
Prior art keywords
insulin
des
human insulin
glu
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013255880A
Other languages
English (en)
Other versions
AU2013255880A1 (en
Inventor
Mads Axelsen
Thue Johansen
Martin Lange
Henriette MERSEBACH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2013255880A1 publication Critical patent/AU2013255880A1/en
Application granted granted Critical
Publication of AU2013255880B2 publication Critical patent/AU2013255880B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2013255880A 2012-05-01 2013-05-01 Pharmaceutical composition Active AU2013255880B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP12166251.4 2012-05-01
EP12166251 2012-05-01
EP12166252.2 2012-05-01
EP12166252 2012-05-01
US201261641544P 2012-05-02 2012-05-02
US201261641540P 2012-05-02 2012-05-02
US61/641,540 2012-05-02
US61/641,544 2012-05-02
PCT/EP2013/059073 WO2013164375A1 (en) 2012-05-01 2013-05-01 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
AU2013255880A1 AU2013255880A1 (en) 2014-10-16
AU2013255880B2 true AU2013255880B2 (en) 2017-07-20

Family

ID=49514218

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013255880A Active AU2013255880B2 (en) 2012-05-01 2013-05-01 Pharmaceutical composition

Country Status (9)

Country Link
US (1) US9884094B2 (cg-RX-API-DMAC7.html)
EP (1) EP2844274B1 (cg-RX-API-DMAC7.html)
JP (1) JP6262206B2 (cg-RX-API-DMAC7.html)
AU (1) AU2013255880B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014026442A8 (cg-RX-API-DMAC7.html)
CA (1) CA2872083A1 (cg-RX-API-DMAC7.html)
MX (1) MX363119B (cg-RX-API-DMAC7.html)
RU (1) RU2670106C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013164375A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074882A1 (en) 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
WO2014147141A1 (en) * 2013-03-20 2014-09-25 Novo Nordisk A/S Insulin dosing regimen
WO2014177623A1 (en) * 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
WO2016001185A1 (en) * 2014-07-02 2016-01-07 Novo Nordisk A/S Dosage regimen for the treatment of diabetes
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2021009027A1 (en) 2019-07-12 2021-01-21 Novo Nordisk A/S High concentration insulin formulation
US20250154220A1 (en) * 2023-11-15 2025-05-15 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0925792A2 (en) * 1997-12-23 1999-06-30 Eli Lilly And Company Insoluble compositions for controlling blood glucose
WO2010049488A1 (en) * 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
WO2012055967A2 (en) * 2010-10-27 2012-05-03 Novo Nordisk A/S Treating diabetes melitus using insulin injections administered with varying injection intervals

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
ES2136595T5 (es) 1989-04-19 2004-04-01 Enzon, Inc. Carbonatos activos de oxidos de polialquileno para la modificacion de polipeptidos.
BR9407508A (pt) 1993-09-17 1997-01-07 Novo Nordisk As Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
PT2275439E (pt) 2003-08-05 2014-06-25 Novo Nordisk As Novos derivados de insulina
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
US20090074882A1 (en) 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
EP2386572B1 (en) 2006-05-09 2015-07-08 Novo Nordisk A/S Insulin derivative
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
MY161892A (en) * 2008-02-19 2017-05-15 Biocon Ltd A method of obtaining a purified, biologically active heterologous protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0925792A2 (en) * 1997-12-23 1999-06-30 Eli Lilly And Company Insoluble compositions for controlling blood glucose
WO2010049488A1 (en) * 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
WO2012055967A2 (en) * 2010-10-27 2012-05-03 Novo Nordisk A/S Treating diabetes melitus using insulin injections administered with varying injection intervals

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GARBER A J ET AL, "Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).", DIABETES, OBESITY & METABOLISM JAN 2006 vol. 8, no. 1, pages 58 - 66 *
STROJEK KRZYSZTOF ET AL, CURRENT MEDICAL RESEARCH AND OPINION DEC 2009 vol. 25, no. 12, pages 2887 - 289 *

Also Published As

Publication number Publication date
MX2014013091A (es) 2014-12-08
RU2014147674A (ru) 2016-06-27
MX363119B (es) 2019-03-11
JP6262206B2 (ja) 2018-01-17
BR112014026442A2 (pt) 2017-06-27
RU2670106C2 (ru) 2018-10-18
WO2013164375A1 (en) 2013-11-07
JP2015517458A (ja) 2015-06-22
EP2844274A1 (en) 2015-03-11
US9884094B2 (en) 2018-02-06
BR112014026442A8 (pt) 2018-01-16
US20150126439A1 (en) 2015-05-07
CA2872083A1 (en) 2013-11-07
AU2013255880A1 (en) 2014-10-16
EP2844274B1 (en) 2019-03-20

Similar Documents

Publication Publication Date Title
AU2013255880B2 (en) Pharmaceutical composition
EP2632478B1 (en) Treating diabetes melitus using insulin injections administered with varying injection intervals
US10137172B2 (en) Administration regime
JP4959005B2 (ja) 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
JP6755175B2 (ja) インスリン投薬レジメン
US20160136246A1 (en) Novel Uses of GLP-1 Receptor Agonists in Patients Treated with Insulin and/or Suffering from Type 1 Diabetes
US10596229B2 (en) Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
ES2724731T3 (es) Composición farmacéutica
Class et al. Patent application title: Novel Administration Regime Inventors: Thue Johansen (Koebenhavn Oe, DK) Ann Marie Ocampo Francisco (Copenhagen V, DK) Torsten Christensen (Princeton, NJ, US) Jens Harald Kongsoe (Hoersholm, DK) Trine Ahlgreen (Frederiksberg C, DK)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)